1. A 73-year-old man with Parkinson's disease on rasagiline 1 mg daily and carbidopa-levodopa 25/100 mg four times daily sustains a displaced femoral neck fracture and is admitted for surgical repair. The anesthesia team notes his rasagiline and asks the orthopedic surgeon to delay surgery five days so the drug can clear. The surgical team contacts the patient's neurologist for guidance. The planned intraoperative and post-operative analgesic regimen includes fentanyl, ketorolac, and acetaminophen. Which of the following represents the most pharmacologically accurate and clinically appropriate response?
A) The five-day delay is appropriate because rasagiline's plasma half-life is approximately five days; proceeding before plasma clearance is complete risks non-selective MAO inhibition from circulating drug, which would interact with fentanyl to produce serotonin syndrome
B) Surgery should be delayed a minimum of 14 days to allow full MAO-B enzyme recovery, and the planned analgesic regimen must be replaced entirely with non-opioid agents; no opioid of any class is safe within two weeks of rasagiline because all opioids carry serotonin syndrome risk with MAO-B inhibitors
C) The five-day delay is unnecessary and surgery can proceed immediately; rasagiline's MAO-B selectivity fully protects against serotonin syndrome with all analgesic agents including fentanyl, and no modification to the analgesic regimen or timing of surgery is required
D) Surgery should proceed immediately but rasagiline must be permanently discontinued; the fracture and surgical stress will produce sufficient catecholamine surge to overcome MAO-B selectivity regardless of the time since last dose, making any future rasagiline use unsafe in this patient
E) Surgery can proceed without delay because the planned analgesic regimen — fentanyl, ketorolac, and acetaminophen — does not include meperidine or tramadol, which are the agents contraindicated with MAO-B inhibitors due to serotonergic interaction risk; fentanyl does not carry the same serotonin reuptake inhibiting mechanism and has been used with appropriate monitoring in patients on MAO-B inhibitors; the five-day delay is pharmacologically unjustified and would expose a fracture patient to unnecessary risk from immobility
ANSWER: E
Rationale:
Option E is correct. The anesthesia team's concern reflects a common but important misconception: that all opioids carry equivalent interaction risk with MAO-B inhibitors. The serotonin syndrome risk with MAO-B inhibitors is specifically associated with opioids that have serotonin reuptake inhibiting properties — primarily meperidine (which is absolutely contraindicated with all MAO-B inhibitors) and tramadol (which carries a serious warning). Fentanyl, in contrast, exerts its analgesic effect through mu-opioid receptor agonism without clinically significant serotonin reuptake inhibition; it does not substantially elevate synaptic serotonin and does not carry the same interaction mechanism. Fentanyl has been used in patients taking MAO-B inhibitors in clinical practice with appropriate monitoring, and it is not contraindicated with rasagiline. Ketorolac is a non-selective NSAID with no serotonergic or MAO-relevant mechanism, and acetaminophen is similarly free of this interaction. The planned analgesic regimen is therefore appropriate. Delaying hip fracture surgery for five days in a 73-year-old patient on anticoagulation prophylaxis, at risk for deep venous thrombosis and pneumonia from immobility, is clinically harmful and pharmacologically unjustified.
Option A: Option A is incorrect because rasagiline's plasma half-life is approximately one to two hours, not five days; the drug is pharmacokinetically cleared rapidly, but MAO-B inhibition persists for two to three weeks due to irreversible covalent binding — neither of these facts supports a five-day delay as the relevant washout period, and fentanyl does not interact via the mechanism that makes meperidine dangerous.
Option B: Option B is incorrect because a 14-day delay for full MAO-B enzyme recovery is relevant only when agents with serotonin reuptake inhibiting properties — such as meperidine or tramadol — must be used and cannot be substituted; since fentanyl and the remainder of this regimen do not carry the serotonergic interaction risk, there is no pharmacological justification for delaying fracture surgery or prohibiting all opioids.
Option C: Option C is incorrect in its absolute reassurance; while the planned regimen is safe, this option incorrectly states that rasagiline's MAO-B selectivity fully protects against serotonin syndrome with all analgesic agents at all doses — selectivity is dose-dependent and does not protect against all serotonergic interactions in all circumstances, so the blanket statement is pharmacologically unsound even though the specific conclusion for this regimen is correct.
Option D: Option D is incorrect because surgical stress does not overcome or invalidate MAO-B selectivity in a pharmacologically meaningful way, and there is no basis for permanently discontinuing rasagiline following fracture surgery; this option fabricates a pharmacodynamic mechanism that does not exist and would deprive the patient of an effective antiparkinsonian medication.
2. A 68-year-old woman with Parkinson's disease on selegiline 5 mg twice daily and carbidopa-levodopa is admitted for a soft tissue infection caused by methicillin-resistant Staphylococcus aureus (MRSA). The infectious disease team proposes linezolid 600 mg intravenously every 12 hours. The consulting pharmacist flags this combination and calls the attending physician. Which of the following most accurately explains the basis for the pharmacist's concern and the appropriate management?
A) Linezolid is a potent inducer of CYP2D6 and will substantially accelerate selegiline's hepatic metabolism to amphetamine metabolites; the resulting surge in l-methamphetamine concentrations will cause severe hypertension and tachycardia requiring selegiline discontinuation and intravenous antihypertensive therapy
B) Linezolid chelates the divalent cations required for MAO-B enzyme function, blocking the active site independently of selegiline; the combination produces additive MAO-B inhibition that will elevate striatal dopamine to toxic levels, manifesting as acute dopaminergic crisis with hyperthermia and rigidity
C) Linezolid is a reversible, non-selective monoamine oxidase inhibitor — a pharmacological property that is a consequence of its oxazolidinone mechanism of action and is independent of its antibiotic activity; co-administration with selegiline creates the equivalent of dual MAO inhibition, substantially increasing serotonin syndrome risk and mandating substitution of an alternative antibiotic or, if linezolid is essential, selegiline discontinuation with appropriate washout before linezolid initiation
D) The concern is limited to the first 48 hours of co-administration, after which linezolid's MAO-inhibiting activity is auto-inactivated by its own metabolites; once auto-inactivation is confirmed by platelet MAO activity assay at 48 hours, both drugs can be continued safely without further restriction
E) The interaction is theoretical rather than clinically significant because selegiline's MAO-B selectivity prevents any meaningful overlap with linezolid's MAO-A inhibitory activity; the two drugs can be co-administered safely provided dietary tyramine is restricted during the period of concurrent use
ANSWER: C
Rationale:
Option C is correct. Linezolid is a reversible, non-selective monoamine oxidase inhibitor — this pharmacological property is intrinsic to the oxazolidinone class and is present at therapeutic antibiotic doses. It is not an incidental or minor property; linezolid's MAO inhibition is clinically significant and the prescribing information for linezolid explicitly warns against co-administration with other serotonergic agents and with MAO inhibitors. When linezolid is added to selegiline therapy, the combined effect is functionally equivalent to dual MAO inhibition: selegiline provides irreversible MAO-B inhibition in the striatum while linezolid adds reversible non-selective MAO inhibition including MAO-A, which impairs serotonin catabolism. The result is marked elevation of synaptic serotonin, creating substantial risk of serotonin syndrome — a potentially life-threatening condition. The appropriate pharmacological response is to substitute an alternative agent effective against MRSA — such as vancomycin, daptomycin, or trimethoprim-sulfamethoxazole depending on infection site and severity — rather than proceed with a combination that carries a well-documented and serious interaction. If linezolid is absolutely necessary and no alternative exists, selegiline must be discontinued with a washout period accounting for its irreversible MAO-B inhibition (two to three weeks for full enzyme recovery) before linezolid can be initiated safely.
Option A: Option A is incorrect because linezolid is not a CYP2D6 inducer; its relevant pharmacological property in this context is MAO inhibition, not CYP enzyme induction, and the mechanism of concern is serotonergic rather than amphetamine-mediated catecholamine release.
Option B: Option B is incorrect because linezolid does not chelate divalent cations to block MAO-B; its MAO inhibitory effect is via reversible binding to the enzyme's active site as a substrate-competitive inhibitor, not through a chelation mechanism, and the clinical concern is serotonin syndrome from MAO-A inhibition, not dopaminergic crisis from additive MAO-B blockade.
Option D: Option D is incorrect because linezolid does not undergo auto-inactivation of its MAO-inhibiting property by its own metabolites at 48 hours; this describes no recognized pharmacological phenomenon, and platelet MAO activity assays are research tools rather than a clinical monitoring strategy used to determine safe continuation of this combination.
Option E: Option E is incorrect because dismissing the interaction based on MAO-B selectivity fundamentally misunderstands the mechanism of concern; the serotonin syndrome risk with linezolid arises from linezolid's own MAO-A inhibition — not from selegiline's MAO-A activity — and dietary tyramine restriction does not address the serotonergic interaction risk that makes this combination dangerous.
3. An 80-year-old man with Parkinson's disease has been stable on carbidopa-levodopa 25/100 mg five times daily for three years. Six weeks ago his neurologist added entacapone 200 mg with each levodopa dose to address worsening wearing-off; his levodopa dose was not adjusted at that time. He now presents to his primary care physician with a two-week history of three near-falls per week, occurring within 60 to 90 minutes of taking his morning levodopa and entacapone. His blood pressure lying is 138/82 mmHg and standing is 96/58 mmHg after one minute. He has no new medications and denies diarrhea, vomiting, or bleeding. His motor control has actually improved since adding entacapone. Which of the following best identifies the mechanism responsible for this presentation and the most appropriate pharmacological adjustment?
A) The orthostatic hypotension is caused by entacapone's increase in levodopa bioavailability augmenting peak dopaminergic exposure; peripheral dopamine receptor activation on splanchnic vascular beds and reduced central sympathetic outflow impair orthostatic cardiovascular compensation; the appropriate first step is a levodopa dose reduction of 10% to 20% at the morning dose to reduce the dopaminergic peak while preserving the improved motor control that entacapone has provided
B) The orthostatic hypotension represents entacapone-induced inhibition of peripheral COMT in sympathetic nerve terminals, reducing norepinephrine synthesis from dopamine and depleting peripheral vasomotor tone; the appropriate management is discontinuation of entacapone and substitution of opicapone, which does not inhibit sympathetic terminal COMT
C) The orthostatic hypotension is caused by entacapone's catechol metabolites directly blocking alpha-1 adrenergic receptors in peripheral resistance arterioles; the appropriate management is addition of midodrine to restore alpha-1 mediated vasoconstriction without modifying the entacapone regimen
D) The presentation reflects entacapone-induced volume depletion from osmotic diarrhea caused by unabsorbed catechol metabolites in the colon; the appropriate management is oral rehydration and dose reduction of entacapone to 100 mg per levodopa dose until volume status normalizes
E) The orthostatic hypotension is caused by entacapone competitively inhibiting the norepinephrine transporter in cardiac sympathetic terminals, reducing heart rate response to orthostatic stress; the appropriate management is addition of pyridostigmine, which enhances ganglionic transmission and restores the heart rate increment on standing
ANSWER: A
Rationale:
Option A is correct. This presentation is a textbook consequence of adding a COMT inhibitor to an existing levodopa regimen without a compensatory dose reduction. Entacapone increases the levodopa area under the plasma concentration-time curve (AUC) by blocking peripheral COMT-mediated methylation of levodopa to 3-O-methyldopa (3-OMD), effectively increasing the dopaminergic signal delivered to the brain and periphery with each dose. In an 80-year-old patient whose cardiovascular autonomic reflexes are already age-impaired, the augmented peak dopaminergic exposure activates peripheral dopamine receptors on splanchnic and renal vascular beds producing vasodilation, and centrally reduces sympathetic outflow, impairing the normal vasoconstriction and heart rate increment that compensate for postural blood pressure change. The clinical picture — orthostatic hypotension appearing within 60 to 90 minutes of the morning dose, corresponding to peak levodopa plasma concentration timing, accompanied by improved motor control confirming effective dopaminergic augmentation — is entirely consistent with this mechanism. The appropriate first step is a modest levodopa dose reduction (10% to 20%) at the morning dose, which will reduce the peak dopaminergic signal while preserving the wearing-off benefit that entacapone has added; entacapone itself does not need to be discontinued.
Option B: Option B is incorrect because entacapone does not inhibit norepinephrine synthesis from dopamine in sympathetic terminals to a clinically meaningful degree; its COMT inhibitory effect on peripheral catecholamine metabolism does not selectively deplete sympathetic norepinephrine in a way that causes orthostatic hypotension, and opicapone shares the same peripheral COMT inhibitory mechanism and would not resolve this adverse effect.
Option C: Option C is incorrect because entacapone's catechol metabolites do not block alpha-1 adrenergic receptors; they are chromogenic catechol compounds excreted in urine that do not have pharmacological activity at adrenergic receptors, and adding midodrine without addressing the underlying dopaminergic excess would leave the causative mechanism untreated.
Option D: Option D is incorrect because entacapone does not cause osmotic diarrhea from unabsorbed catechol metabolites; gastrointestinal adverse effects from COMT inhibitors are related to dopaminergic augmentation (nausea, diarrhea from dopamine receptor stimulation in the gut wall) rather than osmotic effects of unabsorbed metabolites, and no dose reduction of entacapone to 100 mg per dose is pharmacologically supported as an approved strategy.
Option E: Option E is incorrect because entacapone does not inhibit the norepinephrine transporter; it is a COMT inhibitor with no activity at monoamine reuptake transporters, and pyridostigmine's mechanism of enhancing ganglionic cholinergic transmission is a treatment for neurogenic orthostatic hypotension of a different etiology rather than the dopaminergic mechanism responsible for this patient's presentation.
4. A 65-year-old woman with Parkinson's disease has been taking tolcapone for nine months after failing both entacapone and opicapone. Her ALT and AST have been normal at every monitoring check throughout therapy: biweekly for the first six months, then monthly for months seven through nine. She is now entering month ten of therapy and asks her neurologist how often she will need blood tests going forward. Her current ALT is 22 U/L (upper limit of normal 40 U/L) and AST is 19 U/L. Which of the following correctly describes the required liver function test schedule for this patient and the pharmacological justification for maintaining ongoing monitoring?
A) No further liver function monitoring is required after nine months of consistently normal results; the black-box warning monitoring requirement applies only to the first year of therapy, and patients who complete 12 months without transaminase elevation are considered to have demonstrated hepatic tolerance and may continue tolcapone without further testing
B) Liver function tests should be performed annually going forward; after the high-risk first six months have passed without incident, the remaining risk is comparable to other commonly used medications and does not warrant more frequent testing than routine annual metabolic panels
C) Liver function tests should continue monthly indefinitely; the tolcapone black-box warning does not permit any reduction in monitoring frequency after the first six months, and monthly testing must be maintained for the entire duration of therapy regardless of how many normal results have accumulated
D) Liver function tests should now be performed every eight weeks, consistent with the mandatory monitoring schedule specified in tolcapone's black-box warning: biweekly for the first six months, monthly for the next six months, and then every eight weeks thereafter for the duration of therapy; the ongoing monitoring reflects the reality that tolcapone-associated hepatotoxicity can arise at any time during treatment and is not limited to the early months
E) Liver function tests should be reduced to quarterly testing at this stage; quarterly monitoring represents a clinically reasonable compromise between the intensive early schedule and the low residual risk after nine months of normal results, and is consistent with the monitoring practices used for other hepatotoxic drugs at equivalent treatment durations
ANSWER: D
Rationale:
Option D is correct. The tolcapone black-box warning specifies a three-phase monitoring schedule that continues for the entire duration of therapy: liver function tests every two weeks for the first six months, then monthly for the next six months (months seven through twelve), and then every eight weeks thereafter. This patient at month nine has completed the biweekly phase and is in the monthly phase; entering month ten, she is approaching the transition to every-eight-week testing, which is the correct interval to communicate for the period ahead. The ongoing monitoring requirement reflects a fundamental pharmacological reality: tolcapone-associated hepatotoxicity is not confined to the early months of therapy. The three post-marketing cases of fatal fulminant hepatic failure that generated the black-box warning were not all detected in the first weeks of treatment, and the mechanism of idiosyncratic hepatotoxicity — likely involving reactive metabolite formation and immune-mediated injury — can occur at any point during exposure. Consistently normal prior results lower suspicion but do not eliminate risk; monitoring continues because the injury can arise de novo at any time on active drug.
Option A: Option A is incorrect because the black-box warning monitoring requirement has no expiration date after 12 months of normal results; there is no provision that patients who tolerate tolcapone through the first year are exempt from further testing — ongoing every-eight-week monitoring is mandatory for the lifetime of tolcapone therapy.
Option B: Option B is incorrect because annual monitoring does not meet the every-eight-week schedule specified in the black-box warning; reducing monitoring to annual frequency at month nine would leave a patient on a drug with known fatal hepatotoxicity risk without adequate biochemical surveillance for ten-month intervals.
Option C: Option C is incorrect because the black-box warning does permit reduction from monthly to every-eight-week testing after the first twelve months of therapy; maintaining monthly monitoring indefinitely overstates the required frequency for this phase of treatment and unnecessarily burdens the patient without pharmacological justification.
Option E: Option E is incorrect because quarterly monitoring — every three months — does not comply with the every-eight-week (approximately every two months) schedule mandated by the prescribing information; characterizing quarterly monitoring as a reasonable compromise substitutes an unsupported standard for a specific regulatory requirement that cannot be modified by clinical judgment alone.
5. A 71-year-old woman with Parkinson's disease on carbidopa-levodopa 25/100 mg four times daily and rasagiline 1 mg daily has opicapone 50 mg added to address persistent wearing-off between her afternoon and evening doses. She calls the clinic the following morning, confused, saying she took the opicapone with her 7 AM levodopa dose because it seemed logical to take it when she takes her levodopa. She asks whether she should take it with levodopa going forward, and whether taking it in the morning instead of at bedtime will reduce its effectiveness. Which of the following most accurately addresses her question and explains the pharmacological rationale for bedtime dosing?
A) She should continue taking opicapone in the morning with her first levodopa dose; the bedtime timing recommendation is a manufacturer preference to reduce pill burden at breakfast, but opicapone's COMT inhibitory effect is equivalent regardless of when it is taken relative to levodopa because its near-covalent enzyme binding is established within two hours of ingestion and persists throughout the day
B) She should switch to bedtime dosing as prescribed; opicapone's near-covalent COMT binding produces greater than 95% COMT inhibition that persists for approximately 24 hours after each dose regardless of when levodopa is taken, so the drug does not need to be timed with individual levodopa doses — bedtime dosing is preferred because it avoids the need to synchronize with levodopa, minimizes peak-dose dopaminergic adverse effects that could occur if COMT inhibition is established simultaneously with the morning levodopa peak, and ensures continuous protection across all four daily levodopa doses
C) The timing of opicapone is irrelevant to its efficacy but critically important for safety; taking opicapone with the morning levodopa dose will cause excessive peak plasma levodopa concentrations because opicapone and carbidopa competitively inhibit the same COMT enzyme and their combined effect doubles COMT inhibition beyond what either drug achieves alone, requiring the morning levodopa dose to be halved whenever opicapone is taken at that time
D) She should take opicapone at noon rather than either morning or bedtime; opicapone's 24-hour duration of COMT inhibition requires it to be taken at the midpoint of the dosing day to distribute its inhibitory effect symmetrically across morning and evening levodopa doses, and both morning and bedtime administration create an asymmetric inhibitory window that leaves one end of the dosing day under-protected
E) Morning dosing of opicapone is preferred over bedtime dosing for patients also taking rasagiline; because rasagiline's MAO-B inhibitory effect peaks overnight when dopamine turnover is lowest, co-administering opicapone at bedtime creates redundant inhibition during the period of least need, whereas morning opicapone ensures peak COMT inhibition coincides with the period of highest levodopa demand
ANSWER: B
Rationale:
Option B is correct. Opicapone's pharmacodynamic profile — near-covalent COMT binding that maintains greater than 95% inhibition for approximately 24 hours from a single dose — completely decouples the timing of drug administration from the timing of levodopa doses. Unlike entacapone, which must be taken with each levodopa dose because its two-hour half-life means COMT inhibition wanes between doses, opicapone's single bedtime dose establishes COMT inhibition that persists through all of the following day's levodopa administrations regardless of when they occur. Bedtime dosing is specifically chosen for two pharmacological reasons: first, it avoids the need for timing coordination with any individual levodopa dose during waking hours, simplifying the medication regimen; second, it separates the pharmacokinetic peak of opicapone's inhibitory effect from the morning levodopa peak, reducing the risk of transient excessive dopaminergic exposure that might produce nausea, orthostatic hypotension, or dyskinesia if COMT inhibition were established simultaneously with the first morning levodopa peak. The patient's single morning dose will have established adequate COMT inhibition that will be maintained through her subsequent levodopa doses, but she should transition to bedtime dosing going forward as prescribed.
Option A: Option A is incorrect because bedtime timing is not a manufacturer preference for pill-burden reduction; it is a pharmacologically grounded recommendation to optimize the relationship between opicapone's inhibitory profile and levodopa peak-dose exposure, and the characterization of the timing as arbitrary misrepresents the clinical rationale.
Option C: Option C is incorrect because carbidopa does not inhibit COMT; carbidopa is an aromatic amino acid decarboxylase (AADC) inhibitor used to prevent peripheral levodopa conversion to dopamine — it has no COMT inhibitory activity and does not interact with opicapone at the enzyme level.
Option D: Option D is incorrect because opicapone's 24-hour duration of COMT inhibition does not require midpoint dosing for symmetric coverage; the drug's pharmacodynamic profile provides continuous inhibition regardless of when within the 24-hour cycle it is administered, and there is no pharmacological rationale for noon dosing based on symmetric window distribution.
Option E: Option E is incorrect because rasagiline's MAO-B inhibitory effect is sustained and continuous throughout the 24-hour period rather than peaking overnight, and there is no pharmacological interaction between rasagiline and opicapone that makes bedtime co-administration redundant; the two drugs act on entirely different enzymes and their combination at any timing does not produce redundant or wasted inhibitory effect.
6. A 76-year-old man with Parkinson's disease has been stable on safinamide 100 mg daily and carbidopa-levodopa for eight months. Without consulting his neurologist, his pain management physician adds tramadol 50 mg every six hours for chronic lumbar radiculopathy. Seventy-two hours later the patient calls the neurology nurse line reporting agitation, profuse sweating, and bilateral hand tremor that is worse than his baseline Parkinson's tremor. His wife adds that he has been confused since yesterday and felt feverish overnight. Vital signs obtained at an urgent care show temperature 38.8°C, heart rate 118 bpm, and blood pressure 162/96 mmHg. Which of the following most accurately identifies the likely diagnosis, the responsible pharmacological mechanism, and the immediate management?
A) The presentation represents a hypertensive crisis from the tyramine interaction; tramadol competitively inhibits intestinal MAO-A, allowing dietary tyramine to accumulate in the systemic circulation; the immediate management is intravenous phentolamine and discontinuation of tramadol while safinamide is continued at its current dose
B) The presentation represents dopaminergic toxicity from tramadol's weak mu-opioid agonism stimulating mesolimbic dopamine release in a patient whose striatum is sensitized by safinamide; the immediate management is a 50% dose reduction of both safinamide and tramadol with close outpatient monitoring over 48 hours
C) The presentation represents safinamide toxicity from tramadol-induced inhibition of safinamide's hepatic metabolism via CYP2D6, raising safinamide plasma concentrations to supratherapeutic levels that produce non-selective MAO inhibition; the immediate management is tramadol discontinuation and a temporary 50% reduction in safinamide dose until levels normalize over five days
D) The presentation represents neuroleptic malignant syndrome triggered by tramadol's dopamine receptor partial agonist activity in the presence of safinamide's voltage-gated sodium channel blockade; the immediate management is intravenous dantrolene and bromocriptine with discontinuation of both agents
E) The presentation is consistent with serotonin syndrome arising from the combination of safinamide — which has MAO-B inhibitory activity that contributes to reduced serotonin catabolism — with tramadol, which inhibits serotonin reuptake; the synergistic increase in synaptic serotonin produces the classic triad of autonomic instability, neuromuscular abnormalities, and altered mental status; the immediate management is emergency department evaluation, discontinuation of both safinamide and tramadol, supportive care, and consideration of cyproheptadine as a 5-HT2A antagonist
ANSWER: E
Rationale:
Option E is correct. This is serotonin syndrome precipitated by the combination of tramadol and safinamide. The mechanism involves two convergent serotonergic effects: safinamide, as a selective MAO-B inhibitor, reduces the oxidative catabolism of serotonin to a modest but non-negligible degree — particularly at its 100 mg dose, which approaches the upper range of the approved dosing and may have some effect on serotonin availability. More importantly, tramadol has dual analgesic mechanisms: mu-opioid receptor agonism and serotonin reuptake inhibition. The serotonin reuptake inhibiting component is pharmacologically significant, not incidental, and it is the basis for tramadol's listing as a drug to avoid with all MAO-B inhibitors in their prescribing information. When tramadol's serotonin reuptake inhibition is combined with safinamide's contribution to reduced serotonin catabolism, synaptic serotonin rises sufficiently to activate 5-HT1A and 5-HT2A receptors, producing the characteristic serotonin syndrome triad evident in this patient: autonomic instability (hyperthermia, diaphoresis, tachycardia, hypertension), neuromuscular abnormalities (tremor beyond baseline, likely with clonus if examined), and altered mental status (agitation, confusion). The three-day time course from tramadol initiation to symptom onset is consistent. Immediate management requires emergency evaluation, discontinuation of both agents, supportive care for hyperthermia and hemodynamic instability, and consideration of cyproheptadine for 5-HT2A blockade in moderate-to-severe cases.
Option A: Option A is incorrect because tramadol does not inhibit intestinal MAO-A and does not produce tyramine accumulation; the hypertensive crisis of tyramine interaction requires genuine MAO-A inhibition by agents such as phenelzine or linezolid — tramadol's relevant serotonergic mechanism is reuptake inhibition at the serotonin transporter, not MAO-A blockade.
Option B: Option B is incorrect because the clinical picture — hyperthermia, diaphoresis, tachycardia, tremor beyond baseline, and altered mental status — is not consistent with dopaminergic toxicity, which typically produces dyskinesia, nausea, and orthostatic hypotension without fever and without the neuromuscular hyperreactivity pattern of serotonin syndrome; tramadol does not meaningfully stimulate mesolimbic dopamine release.
Option C: Option C is incorrect because tramadol is not a clinically significant CYP2D6 inhibitor in the context of safinamide metabolism, and safinamide does not achieve non-selective MAO inhibition from modest plasma level increases within its therapeutic and supratherapeutic range; this option fabricates a pharmacokinetic interaction pathway and a downstream mechanism that do not account for the clinical presentation.
Option D: Option D is incorrect because neuroleptic malignant syndrome (NMS) requires dopamine receptor blockade — typically from antipsychotic drugs — and presents with lead-pipe rigidity, obtundation, and markedly elevated creatine kinase developing over days; tramadol is not a dopamine receptor antagonist, safinamide has no dopamine receptor-blocking activity, and the clinical features here are more consistent with serotonin syndrome than NMS.
7. A 69-year-old woman is newly diagnosed with Parkinson's disease and moderate major depressive disorder. Her neurologist plans to start a MAO-B inhibitor as initial antiparkinson therapy and asks psychiatry to recommend an antidepressant. The psychiatrist proposes options including paroxetine, venlafaxine, bupropion, and sertraline. The patient has no cardiac history, no significant renal or hepatic impairment, and is not taking any other medications. Which of the following combinations and monitoring plans represents the most pharmacologically defensible approach?
A) Paroxetine and rasagiline represent the safest combination because paroxetine's potent CYP2D6 inhibition will reduce rasagiline's conversion to any active metabolites, lowering the effective rasagiline exposure and thereby reducing the serotonergic interaction risk to negligible levels while providing robust antidepressant efficacy
B) Venlafaxine and safinamide represent the preferred combination because venlafaxine's dual serotonin and norepinephrine reuptake inhibition produces antidepressant effects that are mechanistically complementary to safinamide's glutamate-reducing sodium channel action, and the two drugs share no pharmacokinetic interactions; no additional monitoring beyond routine psychiatric follow-up is required
C) Rasagiline plus sertraline represents a reasonable and widely used combination, with the caveat that the serotonin syndrome risk, while substantially lower than with non-selective MAOIs, is not zero; the patient should be started on a low sertraline dose, educated about serotonin syndrome symptoms — agitation, tremor, diaphoresis, hyperthermia — and monitored closely at initiation and at any dose increase of either drug; paroxetine should be specifically avoided because its potent CYP2D6 inhibition raises rasagiline plasma concentrations and amplifies the serotonergic interaction risk through a pharmacokinetic mechanism
D) Bupropion and any MAO-B inhibitor represent the safest pairing because bupropion's mechanism — dopamine and norepinephrine reuptake inhibition — carries no serotonergic activity and therefore produces no serotonin syndrome risk regardless of which MAO-B inhibitor is selected; no monitoring beyond standard psychiatric follow-up is required and the combination requires no dose adjustment of either agent
E) No antidepressant should be started concurrently with any MAO-B inhibitor in a newly diagnosed Parkinson's disease patient; depression should be managed with cognitive behavioral therapy alone for a minimum of six months before any pharmacological antidepressant therapy is introduced, because the neuropsychiatric risk of all antidepressant-MAO inhibitor combinations outweighs the benefit in this clinical context
ANSWER: C
Rationale:
Option C is correct. Rasagiline plus sertraline is a combination supported by observational evidence of a generally tolerable safety profile and represents the most pharmacologically defensible choice among the options presented, provided it is accompanied by appropriate patient education and monitoring. Sertraline is a selective serotonin reuptake inhibitor (SSRI) with relatively modest serotonin reuptake inhibitory potency compared to paroxetine, a clean pharmacokinetic profile, and no meaningful CYP1A2 inhibition that would raise rasagiline concentrations. The serotonin syndrome risk of rasagiline combined with an SSRI is substantially lower than with non-selective MAOIs because rasagiline's selectivity for MAO-B leaves MAO-A — the primary enzyme catabolizing serotonin — largely intact. However, the risk is not zero, and starting at a low sertraline dose with symptom-directed monitoring at initiation and dose changes is appropriate clinical practice. Paroxetine is specifically contraindicated in this context for a separate reason: it is a potent CYP2D6 inhibitor, and while rasagiline is primarily metabolized by CYP1A2, paroxetine's broad CYP inhibitory profile also affects CYP1A2 to some degree, potentially raising rasagiline plasma concentrations — compounding the serotonergic interaction risk through a pharmacokinetic mechanism on top of the pharmacodynamic one.
Option A: Option A is incorrect on two counts: first, rasagiline is not primarily metabolized by CYP2D6 but by CYP1A2, so paroxetine's CYP2D6 inhibition is not the primary relevant pharmacokinetic interaction for rasagiline; second, the premise that CYP inhibition reduces rather than raises drug exposure is inverted — inhibiting the metabolizing enzyme increases plasma drug concentrations, it does not reduce them.
Option B: Option B is incorrect because venlafaxine's dual serotonin and norepinephrine reuptake inhibiting mechanism makes it a more potent serotonergic agent than sertraline in the context of a MAO-B inhibitor; the combination of venlafaxine with any MAO-B inhibitor carries a higher serotonin syndrome risk than an SSRI-MAO-B combination, and dismissing this risk as negligible is pharmacologically unsound; the statement that no additional monitoring is required is therefore incorrect.
Option D: Option D is incorrect because bupropion, while lacking serotonergic reuptake inhibition, has seizure-lowering threshold effects and dopaminergic/noradrenergic activity that warrants consideration in a patient on a dopaminergic antiparkinson regimen, and more importantly, the claim that the combination requires no monitoring or dose adjustment reflects overconfidence given that bupropion's dopaminergic amplification on top of MAO-B inhibition can produce neuropsychiatric adverse effects; additionally, bupropion is not typically considered a first-line antidepressant for Parkinson's disease-associated depression in current practice.
Option E: Option E is incorrect because denying pharmacological antidepressant treatment to a patient with moderate major depressive disorder for six months is not supported by evidence or guideline recommendations; depression in Parkinson's disease is underrecognized and undertreated, and an arbitrarily prolonged delay in antidepressant therapy based on a categorical prohibition of all combinations is not consistent with evidence-based psychiatric practice.
8. A 74-year-old man with Parkinson's disease takes carbidopa-levodopa 25/100 mg five times daily and entacapone 200 mg with each levodopa dose. Despite this regimen he has three to four hours of daily off time and mild peak-dose dyskinesia affecting his right arm during each on period. His neurologist plans to add rasagiline 1 mg daily to further reduce off time. Before writing the prescription, which of the following most accurately describes the required levodopa dose adjustment and its pharmacological justification?
A) The levodopa dose should be reduced by 10% to 20% before or at the time rasagiline is initiated; rasagiline's MAO-B inhibition will reduce striatal dopamine catabolism, increasing the effective dopaminergic signal delivered by each levodopa dose on top of the existing COMT inhibition from entacapone; in a patient with pre-existing peak-dose dyskinesia, this additive augmentation will predictably worsen dyskinesia unless the levodopa dose is proactively reduced to bring total dopaminergic exposure back within the tolerable window
B) No levodopa dose adjustment is needed because rasagiline acts centrally on already-released dopamine and does not alter the pharmacokinetics of levodopa absorption or plasma AUC; since entacapone already accounts for peripheral levodopa metabolism, adding rasagiline produces no additional change in the amount of levodopa reaching the brain per dose
C) The levodopa dose should be increased by 10% to 15% when rasagiline is added; rasagiline's MAO-B inhibition will compete with the COMT pathway for dopamine substrate, reducing entacapone's ability to prevent 3-O-methyldopa formation and decreasing effective levodopa bioavailability; a dose increase compensates for this pharmacokinetic antagonism
D) The entacapone dose, not the levodopa dose, should be reduced when rasagiline is added; because both agents augment dopaminergic exposure through independent mechanisms, their additive effect is best managed by lowering entacapone from 200 mg to 100 mg per levodopa dose, which has been shown to produce a net dopaminergic effect equivalent to single-agent adjunction without increasing dyskinesia risk
E) Both the levodopa and the entacapone doses should be reduced simultaneously before rasagiline is started; the combination of all three agents produces supralinear dopaminergic augmentation that cannot be safely managed by adjusting only one component of the regimen, and a 25% reduction in both levodopa and entacapone is required by the prescribing guidelines for triple adjunct therapy
ANSWER: A
Rationale:
Option A is correct. This question requires integrating the additive pharmacodynamic consequences of combining two different classes of dopaminergic adjuncts — a COMT inhibitor (entacapone) already in place and a MAO-B inhibitor (rasagiline) being added — in a patient who already shows evidence of striatal sensitization through pre-existing peak-dose dyskinesia. Entacapone is already increasing the levodopa AUC by blocking peripheral COMT-mediated methylation of levodopa to 3-OMD, delivering more levodopa to the brain per dose. Rasagiline will add a separate layer of dopaminergic augmentation by slowing the MAO-B-mediated catabolism of dopamine within the striatum after it is formed from levodopa. The two mechanisms are additive in their net effect on total dopaminergic exposure — as demonstrated clinically in the STRIDE-PD trial, which found that the combination of levodopa, carbidopa, and entacapone produced more dyskinesia than levodopa and carbidopa alone. In a patient who already has peak-dose dyskinesia on the existing two-drug regimen, adding rasagiline without a compensatory levodopa dose reduction will predictably push total effective dopaminergic exposure further above the dyskinesia threshold. A proactive levodopa dose reduction of 10% to 20% — implemented at the time rasagiline is started — preserves the additional off-time benefit while containing dyskinesia.
Option B: Option B is incorrect because while rasagiline does not alter levodopa pharmacokinetics or peripheral absorption, its pharmacodynamic effect on striatal dopamine catabolism does increase the effective dopaminergic signal reaching postsynaptic receptors, which is pharmacologically equivalent to delivering a higher dopaminergic stimulus per levodopa dose; stating that no dose adjustment is needed ignores this additive pharmacodynamic mechanism.
Option C: Option C is incorrect because rasagiline and the COMT pathway are pharmacologically independent: rasagiline inhibits MAO-B in the striatum while entacapone inhibits peripheral COMT — these are different enzymes acting on different substrates at different anatomical locations, and MAO-B inhibition does not compete with or reduce COMT activity; the concept of pharmacokinetic antagonism between these two pathways has no pharmacological basis.
Option D: Option D is incorrect because entacapone does not come in a 100 mg formulation; it is available only as a fixed 200 mg dose co-administered with each levodopa administration, and there is no approved strategy of reducing the entacapone dose to manage additive dopaminergic effects — the adjustment for combined adjunct therapy is made to the levodopa dose.
Option E: Option E is incorrect because neither guideline recommendation nor established prescribing practice requires simultaneous reduction of both levodopa and entacapone before adding rasagiline; the additive dopaminergic effect is managed by a single adjustment to the levodopa dose, and the concept of supralinear augmentation requiring mandatory dual reduction for triple adjunct therapy does not reflect pharmacological evidence or regulatory guidance.
9. A 67-year-old man with Parkinson's disease has been on tolcapone for 14 months with excellent motor control and entirely normal liver function tests at every scheduled check. He presents to his neurologist and says he finds the every-eight-week blood draws burdensome and asks to stop monitoring. He states that 14 months of normal results means his liver is clearly tolerating the drug and the testing is no longer necessary. He asks: "If my liver was going to be damaged, wouldn't it have happened by now?" Which of the following most accurately responds to his question and explains why the monitoring schedule must be maintained?
A) His reasoning is correct; 14 months of normal liver function tests demonstrates established hepatic tolerance to tolcapone, and the every-eight-week monitoring schedule can be safely reduced to annual testing at this stage, consistent with the approach used for other long-term medications with hepatic adverse effect profiles
B) The monitoring can be stopped if the patient signs a formal waiver acknowledging the hepatotoxicity risk; the black-box warning monitoring schedule represents a recommended rather than mandatory standard, and informed refusal by a competent patient overrides the requirement as long as the decision is documented in the medical record
C) The monitoring schedule should be maintained but can be modified to a self-reported symptom protocol; the patient should be instructed to seek liver function testing only if he develops jaundice, dark urine, or right upper quadrant pain, because symptomatic hepatotoxicity universally precedes biochemical injury and the monitoring schedule is designed to catch symptoms rather than silent transaminase elevations
D) The monitoring must continue at every-eight-week intervals for the duration of tolcapone therapy regardless of how many normal results have accumulated; the three post-marketing cases of fatal fulminant hepatic failure that generated the black-box warning demonstrate that tolcapone-associated hepatotoxicity can arise at any point during treatment without prior signal, and the patient's 14 months of normal results do not confer protection against injury in month 15 or beyond — the monitoring exists precisely because the injury cannot be predicted from prior test results
E) The monitoring frequency can be reduced to every six months at this stage because the risk of tolcapone hepatotoxicity follows a bathtub curve, with highest risk in the first three months and negligible risk after 12 months; the every-eight-week schedule is designed for the first year and is pharmacologically unnecessary thereafter in patients with sustained normal results
ANSWER: D
Rationale:
Option D is correct. The patient's intuition — that prior normal results predict future safety — is a common and understandable misconception, but it is pharmacologically incorrect for tolcapone. The three cases of fatal fulminant hepatic failure that occurred post-marketing did not necessarily follow a pattern of progressive transaminase elevation that would have been detected and acted upon by prior monitoring; idiosyncratic hepatotoxicity can arise acutely and without antecedent biochemical warning. The purpose of the monitoring schedule is not to confirm that the liver has already tolerated the drug, but to detect the onset of injury as early as possible so that the drug can be discontinued before irreversible hepatic failure occurs. Fourteen months of normal results reduces a physician's suspicion of ongoing injury but cannot guarantee that the liver's response to tolcapone has been permanently established as safe. The black-box warning mandates every-eight-week testing for the duration of therapy without any provision for discontinuing or relaxing the schedule based on accumulation of normal results — the schedule is mandatory, not probabilistic. The neurologist must clearly explain this to the patient and document the conversation, but the monitoring requirement cannot be waived at the patient's request.
Option A: Option A is incorrect because 14 months of normal results does not establish hepatic tolerance; tolcapone's hepatotoxicity is idiosyncratic and can occur at any time during treatment, and no evidence supports reducing the mandated every-eight-week frequency to annual monitoring — this is not consistent with the prescribing information or with sound clinical pharmacology.
Option B: Option B is incorrect because the monitoring schedule is a mandatory regulatory requirement embedded in the black-box warning and the drug's risk evaluation and mitigation strategy (REMS); it is not optional and cannot be waived by patient informed refusal in the same way that a diagnostic recommendation might be declined — prescribing tolcapone without adherence to its monitoring requirements exposes both patient and prescriber to unacceptable risk.
Option C: Option C is incorrect because symptomatic hepatotoxicity does not universally precede biochemical injury with tolcapone; the monitoring schedule exists specifically because the progression from biochemical transaminase elevation to clinical hepatic failure can be rapid, and waiting for symptoms to appear before testing is the approach that allowed one or more of the fatal post-marketing cases to progress to fulminant failure — symptom-triggered testing is explicitly insufficient.
Option E: Option E is incorrect because there is no pharmacological evidence that tolcapone hepatotoxicity follows a bathtub curve with negligible risk after 12 months; the post-marketing cases did not all occur in the first three months of therapy, and no study or regulatory document supports the notion that risk becomes negligible after the first year — this option fabricates a risk distribution that has no empirical basis.
10. A 72-year-old woman with Parkinson's disease has been on carbidopa-levodopa 25/100 mg four times daily and opicapone 50 mg at bedtime for four months. At follow-up she reports that her wearing-off has improved considerably on days when she remembers to take the opicapone, but on other days — approximately three nights per week — she forgets the bedtime dose entirely and notices more pronounced wearing-off the following day. She asks whether she can take the missed opicapone dose in the morning when she remembers, or whether she should simply skip it on days she forgets. Which of the following most accurately explains the pharmacodynamic consequence of missed doses and provides the most appropriate practical guidance?
A) She should take the missed opicapone dose in the morning as soon as she remembers; opicapone's COMT inhibitory effect requires the drug to be present in plasma simultaneously with levodopa to function, so morning administration will restore COMT inhibition just in time to protect her first morning levodopa dose and rescue the day's pharmacological coverage
B) She should not take a missed opicapone dose in the morning; opicapone's near-covalent COMT binding means that when a bedtime dose is missed, COMT inhibition is substantially reduced by morning — allowing normal 3-O-methyldopa formation from her morning levodopa doses — which explains her increased wearing-off on those days; however, taking opicapone in the morning risks overlapping its inhibitory peak with her morning levodopa peak, potentially producing excessive dopaminergic exposure including nausea or dyskinesia; the correct approach is to simply take the next scheduled bedtime dose without doubling up, and to work with her neurologist on adherence strategies such as a phone alarm at bedtime
C) She should take the missed opicapone dose immediately upon waking regardless of timing, because opicapone's half-life is 24 hours and a morning dose will re-establish COMT inhibition within two hours; the morning dose is pharmacokinetically equivalent to the bedtime dose for all practical purposes and produces no additional peak-dose risk when taken with the first morning levodopa
D) The missed dose has no meaningful clinical consequence; because opicapone achieves greater than 95% COMT inhibition at steady state and the enzyme pool requires seven to ten days to fully replenish after a single missed dose, skipping three nights per week does not materially reduce COMT inhibition on the following day — her wearing-off on those days is attributable to disease progression rather than the missed opicapone
E) She should take twice the standard dose — 100 mg — on evenings following a missed night to compensate for the prior day's under-inhibition of COMT; double dosing is safe because opicapone's near-covalent binding means excess drug beyond full enzyme saturation is simply excreted without additional pharmacodynamic effect, and the compensatory dose will restore the cumulative COMT inhibition that the missed dose failed to provide
ANSWER: B
Rationale:
Option B is correct. This question integrates opicapone's unusual pharmacodynamic profile with practical adherence management. Opicapone's near-covalent COMT binding sustains greater than 95% COMT inhibition for approximately 24 hours from a single dose, meaning that when a bedtime dose is taken as scheduled, COMT inhibition is maintained through all of the following day's levodopa administrations. When the bedtime dose is missed, COMT activity begins to recover as the prior night's opicapone dissociates from the enzyme; by morning — 8 to 12 hours after the scheduled dose was missed — COMT inhibition has declined substantially, allowing increased methylation of levodopa to 3-OMD and reducing levodopa AUC. This explains the patient's observation of worse wearing-off on days after a missed dose. Taking opicapone in the morning rather than at bedtime is not recommended because morning administration establishes peak COMT inhibition simultaneously with the first morning levodopa dose, potentially producing excessive peak dopaminergic exposure — nausea, dyskinesia, or orthostatic hypotension — that the bedtime timing strategy specifically avoids. The correct advice is to skip the missed dose, take the next bedtime dose as scheduled, and address adherence through behavioral strategies.
Option A: Option A is incorrect because opicapone's pharmacological action does not require simultaneous plasma presence with levodopa; its COMT inhibition is established by enzyme binding and persists after the drug is cleared from plasma — the rationale in this option misapplies entacapone's simultaneous co-dosing rationale to opicapone's pharmacodynamically distinct mechanism.
Option C: Option C is incorrect because opicapone's plasma half-life is not 24 hours — its extended pharmacodynamic duration is due to near-covalent enzyme binding, not pharmacokinetic persistence; the claim that morning dosing is pharmacokinetically equivalent to bedtime dosing ignores the peak-dose dopaminergic adverse effect risk that bedtime timing specifically avoids by separating opicapone's inhibitory establishment from the morning levodopa peak.
Option D: Option D is incorrect because a missed dose does have a meaningful clinical consequence — COMT activity recovers within hours of a missed dose because opicapone's binding, while near-covalent, does gradually dissociate and is not permanent; the enzyme pool does not require seven to ten days to replenish after a single missed dose, and the patient's own report of worse wearing-off on days following missed doses confirms the pharmacodynamic impact.
Option E: Option E is incorrect because doubling the opicapone dose to 100 mg is not an approved dosing strategy, does not reflect any recommendation in the prescribing information, and is not pharmacologically justified by the claim that excess drug beyond full enzyme saturation is harmlessly excreted; while some excess may be excreted, doubling the dose is not established as safe and could produce supratherapeutic plasma concentrations with unpredictable adverse effects.
11. A 78-year-old woman with Parkinson's disease on rasagiline 1 mg daily and carbidopa-levodopa presents to the emergency department with severe right-sided flank pain radiating to the groin. Renal ultrasound reveals a 6 mm ureteral calculus. She is in significant distress and requires analgesia. The emergency physician considers the following options: meperidine 50 mg intravenously, tramadol 50 mg orally, hydromorphone 0.2 mg intravenously, ketorolac 15 mg intravenously, and dextromethorphan 30 mg orally for its antispasmodic properties. Which of the following analgesic choices is pharmacologically safe and appropriate in this patient?
A) Meperidine 50 mg intravenously is safe at this reduced dose because the absolute contraindication with MAO-B inhibitors applies only to doses above 100 mg; at 50 mg the serotonergic interaction risk is below the threshold for serotonin syndrome in patients on selective MAO-B inhibitors such as rasagiline
B) Tramadol 50 mg orally is appropriate because tramadol's interaction risk with MAO-B inhibitors applies only when the MAO-B inhibitor has been taken within the preceding 24 hours; the patient's morning rasagiline dose was more than 12 hours ago, placing her outside the interaction window for tramadol administration
C) Ketorolac 15 mg intravenously combined with hydromorphone 0.2 mg intravenously provides effective multimodal analgesia for ureteral colic and is pharmacologically safe in this patient; neither ketorolac nor hydromorphone carries a contraindication or serious interaction warning with rasagiline — ketorolac is a non-selective NSAID with no serotonergic mechanism and hydromorphone is a pure mu-opioid agonist without serotonin reuptake inhibiting properties
D) Dextromethorphan 30 mg orally is appropriate for ureteral calculus-associated smooth muscle spasm and has no meaningful pharmacological interaction with rasagiline at this dose; its antispasmodic properties will reduce ureteral tone while avoiding the opioid and serotonergic risks of the other agents
E) No opioid analgesic can be safely administered to this patient while she is taking rasagiline; ureteral colic must be managed exclusively with non-opioid agents including ketorolac, and if pain control is inadequate, rasagiline must be discontinued and a two-week washout period completed before any opioid may be considered
ANSWER: C
Rationale:
Option C is correct. Ketorolac and hydromorphone together represent a pharmacologically sound multimodal analgesic regimen for ureteral colic in this patient. Ketorolac is a non-selective cyclooxygenase (COX) inhibitor with no monoamine oxidase-relevant mechanism, no serotonin reuptake inhibiting activity, and no pharmacological interaction with rasagiline; it provides effective prostaglandin-mediated analgesia and reduces ureteral smooth muscle spasm. Hydromorphone is a potent mu-opioid receptor agonist that exerts its analgesic effect through opioid receptor activation without serotonin reuptake inhibiting properties; unlike meperidine and tramadol, it does not carry the serotonergic interaction warning with MAO-B inhibitors and can be used with appropriate monitoring in patients taking rasagiline. The combination addresses renal colic through both anti-inflammatory and opioid mechanisms and avoids every agent contraindicated or warned against with MAO-B inhibitors.
Option A: Option A is incorrect because meperidine is absolutely contraindicated with all MAO-B inhibitors at any dose; there is no threshold below which meperidine becomes safe in this setting — the contraindication is not dose-dependent, and the prescribing information for rasagiline specifies meperidine as absolutely contraindicated regardless of the dose administered.
Option B: Option B is incorrect because the rasagiline-tramadol interaction is not time-limited by when the most recent rasagiline dose was taken; rasagiline produces irreversible MAO-B inhibition that persists for two to three weeks after the last dose as the enzyme recovers through de novo synthesis, and the 12-hour interval since the morning dose is entirely irrelevant to the duration of MAO-B inhibition — tramadol remains contraindicated regardless of timing within the dosing cycle.
Option D: Option D is incorrect because dextromethorphan carries an explicit interaction warning with MAO-B inhibitors including rasagiline — it is listed alongside meperidine and tramadol as an agent to avoid in the prescribing information; dextromethorphan's serotonin reuptake inhibiting and sigma receptor activity creates a serotonin syndrome risk with MAO-B inhibitors, and using it for antispasmodic purposes in this patient is pharmacologically contraindicated.
Option E: Option E is incorrect because the prohibition on opioids with rasagiline is not a class-wide absolute contraindication; it applies specifically to opioids with serotonin reuptake inhibiting properties — primarily meperidine and tramadol — and not to pure mu-opioid agonists such as hydromorphone, oxycodone, morphine, or fentanyl; withholding all opioids and requiring a two-week washout before adequate analgesia can be provided would expose the patient to unnecessary pain and is not supported by pharmacological evidence.
This Web-based pharmacology and disease-based integrated teaching site is based on reference materials that are believed reliable and consistent with standards accepted at the time of development.
Possibility of error and on-going research and development in medical sciences do not allow assurance that the information contained herein is in every respect accurate or complete.
Users should confirm the information contained herein with other sources.
This site should only be considered as a teaching aid for undergraduate and graduate biomedical education and is intended only as a teaching site.
Information contained here should not be used for patient management and should not be used as a substitute for consultation with practicing medical professionals.
Users of this website should check the product information sheet included in the package of any drug they plan to administer to be certain that the information contained in this site is accurate and that changes have not been made in the recommended dose or in the contraindications for administration.
Medical or other information thus obtained should not be used as a substitute for consultation with practicing medical or scientific or other professionals.